Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ILMN US Equity

Illumina, Inc.Health Care · Laboratory Analytical Instruments · CIK 1110803 · FY ends Jan 3
$205.00
+16.71 (+8.87%)
USD · as of 2026-08-19 · marketstack

ILMN · 10-K · period ended 2023-01-01

← all ILMN documents
filed 2023-02-17 · EDGAR original ↗

Our rendering of the filing — original pagination and typography are not reproduced, and tables are reduced to their short label cells (the figures live on FA). Nothing is summarized: every line below is the filing's own text.

blocks 1,5051,554 of 1,554335k characters rendered

Item 1A Risk Factors 14

Item 1B Unresolved Staff Comments None

Item 2 Properties 11

Item 3 Legal Proceedings 28

Item 4 Mine Safety Disclosures Not Applicable

PART II

Item 7A Quantitative and Qualitative Disclosures About Market Risk 42

Item 8 Financial Statements and Supplementary Data 44

Item 9A Controls and Procedures 90

Item 9B Other Information None

PART III

Item 10 Directors, Executive Officers and Corporate Governance 92

Item 11 Executive Compensation 92

Item 14 Principal Accountant Fees and Services 93

PART IV

Item 15 Exhibits, Financial Statement Schedules 93

Signatures 99

98

Table of Contents

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 17, 2023.

ILLUMINA, INC.

By /s/ FRANCIS A. DESOUZA

Francis A. deSouzaChief Executive Officer

99

Table of Contents

February 17, 2023

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Francis A. deSouza and Joydeep Goswami, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his, or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Francis A. deSouza

Joydeep Goswami

Scott Ericksen

/s/ JOHN W. THOMPSON Chairman of the Board of Directors February 17, 2023

John W. Thompson

/s/ FRANCES ARNOLD Director February 17, 2023

Frances Arnold, Ph.D.

/s/ CAROLINE D. DORSA Director February 17, 2023

Caroline D. Dorsa

/s/ ROBERT S. EPSTEIN Director February 17, 2023

Robert S. Epstein, M.D.

/s/ SCOTT GOTTLIEB Director February 17, 2023

Scott Gottlieb, M.D.

/s/ GARY S. GUTHART Director February 17, 2023

Gary S. Guthart, Ph.D.

/s/ PHILIP W. SCHILLER Director February 17, 2023

Philip W. Schiller

/s/ SUSAN E. SIEGEL Director February 17, 2023

Susan E. Siegel

100

End of the document.
Source: SEC EDGAR (public domain) · 10-K for the period ended 2023-01-01, filed 2023-02-17 · accession 0001110803-23-000023

Filing HTML rendered to line-structured narrative text by the shipped reducer (datafeeds.edgar_fulltext.visible_text, keep_table_headers=True): scripts and inline-XBRL headers are dropped, and table content is reduced to its short label cells — numeric table data is not rendered and is therefore not counted. The same rendering is used for every year, so a year-over-year comparison is like for like.

The text is our rendering of the filing, not a facsimile: original pagination, typography and tables are not reproduced, and the numbers live in the financial statements (FA).

The outline locates item HEADINGS in this document. Only Items 1A and 7 have certified boundaries elsewhere in the terminal (the redline and the narrative-overlap number); every span here runs from one heading found to the next heading found.

How the outline was chosen. It is the longest chain of item headings that runs forward through both the document and the standard item order: 14 headings are on that chain and 0 further heading-shaped lines are not — the table-of-contents echo of every item, cross-references and exhibit-list mentions. Each entry's length is measured from its heading to the next heading on the chain.